Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRMD Stock Forecast 2025-2026
$11.69
Current Price
$788.12M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CRMD Price Targets
+71.1%
To High Target of $20.00
+45.4%
To Median Target of $17.00
+11.2%
To Low Target of $13.00
CRMD Price Momentum
+0.3%
1 Week Change
+55.5%
1 Month Change
+124.8%
1 Year Change
+44.3%
Year-to-Date Change
-15.6%
From 52W High of $13.85
+223.8%
From 52W Low of $3.61
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching CorMedix (CRMD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CRMD and similar high-potential opportunities.
Latest CRMD Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, CRMD has a bullish consensus with a median price target of $17.00 (ranging from $13.00 to $20.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $11.69, the median forecast implies a 45.4% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Brandon Folkes at Rodman & Renshaw, suggesting a 11.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRMD Analyst Ratings
6
Buy
0
Hold
0
Sell
CRMD Price Target Range
Low
$13.00
Average
$17.00
High
$20.00
Current: $11.69
Latest CRMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2025 | Needham | Serge Belanger | Buy | Maintains | $15.00 |
| May 6, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $15.00 |
| Apr 9, 2025 | Needham | Serge Belanger | Buy | Reiterates | $12.00 |
| Apr 8, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $15.00 |
| Mar 26, 2025 | RBC Capital | Gregory Renza | Outperform | Reiterates | $12.00 |
| Mar 26, 2025 | Needham | Serge Belanger | Buy | Maintains | $12.00 |
| Mar 25, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $15.00 |
| Mar 7, 2025 | Leerink Partners | Roanna Ruiz | Outperform | Initiates | $18.00 |
| Mar 5, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $15.00 |
| Jan 22, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $15.00 |
| Jan 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Initiates | $15.00 |
| Dec 19, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $12.00 |
| Oct 31, 2024 | Needham | Serge Belanger | Buy | Maintains | $18.00 |
| Oct 22, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $17.00 |
| Aug 26, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Initiates | $13.00 |
| Aug 15, 2024 | Needham | Serge Belanger | Buy | Reiterates | $10.00 |
| Aug 15, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $9.00 |
| Jul 25, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $12.00 |
| Jun 19, 2024 | Needham | Serge Belanger | Buy | Reiterates | $10.00 |
| May 13, 2024 | Needham | Serge Belanger | Buy | Reiterates | $10.00 |
CorMedix Inc. (CRMD) Competitors
The following stocks are similar to CorMedix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CorMedix Inc. (CRMD) Financial Data
CorMedix Inc. has a market capitalization of $788.12M with a P/E ratio of 46.5x. The company generates $82.55M in trailing twelve-month revenue with a 20.8% profit margin.
Revenue growth is +25.2% quarter-over-quarter, while maintaining an operating margin of +51.5% and return on equity of +19.9%.
Valuation Metrics
Market Cap
$788.12M
Enterprise Value
$711.77M
P/E Ratio
46.5x
PEG Ratio
24.2x
Price/Sales
9.5x
Growth & Margins
Revenue Growth (YoY)
+25.2%
Gross Margin
+95.9%
Operating Margin
+51.5%
Net Margin
+20.8%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+9.8%
Current Ratio
4.2x
Debt/Equity
0.4x
ROE
+19.9%
ROA
+8.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
CorMedix Inc. (CRMD) Business Model
About CorMedix Inc.
What They Do
Develops therapeutic products for infectious diseases.
Business Model
CorMedix Inc. generates revenue by developing and commercializing therapeutic products, particularly focusing on its flagship product, Defencath, which aims to prevent catheter-related bloodstream infections. The company targets a significant medical need and seeks regulatory approvals and partnerships to enhance its market presence and product applications.
Additional Information
With a strong emphasis on patient safety and improving healthcare outcomes, CorMedix is actively engaged in clinical trials and ongoing product development. The company's innovative solutions are positioned within the competitive biopharmaceutical sector, addressing both infection prevention and patient care demands.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
64
CEO
Mr. Joseph Todisco MBA
Country
United States
IPO Year
2010
Website
www.cormedix.comCorMedix Inc. (CRMD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
May 09, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
CorMedix Inc. (Nasdaq: CRMD) will participate in the RBC Capital Markets Global Healthcare Conference in New York on May 20-21, 2025, focusing on biopharmaceutical developments.
Why It Matters
CorMedix's participation in a major healthcare conference highlights its visibility and potential growth in the biopharmaceutical sector, signaling opportunities for investment interest and market movement.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CorMedix (CRMD) shares are gaining momentum, potentially continuing upward due to positive earnings estimate revisions.
Why It Matters
Rising earnings estimates suggest improved financial performance for CorMedix (CRMD), potentially boosting investor confidence and share prices.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
CorMedix, Inc. (NASDAQ:CRMD) will hold its Q1 2025 earnings conference call on May 6, 2025, at 8:30 AM ET, featuring key executives and analysts from multiple firms.
Why It Matters
The earnings conference call provides insights into CorMedix's financial performance and strategic direction, influencing investor sentiment and stock price movements.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Q1 2025 reported net revenue of $39.1 million and adjusted EBITDA of $23.6 million. A conference call is scheduled for today at 8:30 a.m. Eastern Time.
Why It Matters
Strong Q1 2025 revenue and EBITDA figures suggest robust financial performance, potentially boosting investor confidence and stock value. The upcoming conference call may provide further insights.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CorMedix (CRMD) reported Q3 earnings of $0.30 per share, surpassing the Zacks Consensus Estimate of $0.25, and improving from a loss of $0.25 per share a year earlier.
Why It Matters
CorMedix's earnings beat expectations, signaling strong financial performance and growth potential, which can enhance investor confidence and potentially boost the stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025
16 days ago
Quick Summary
CorMedix Inc. (Nasdaq: CRMD) will report Q1 2025 financial results on May 6, 2025, before market open, followed by a conference call at 8:30 AM ET.
Why It Matters
CorMedix's upcoming financial results and conference call could influence stock performance, offering insights into its growth prospects and market positioning.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CRMD Stock
What is CorMedix Inc.'s (CRMD) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, CorMedix Inc. (CRMD) has a median price target of $17.00. The highest price target is $20.00 and the lowest is $13.00.
Is CRMD stock a good investment in 2025?
According to current analyst ratings, CRMD has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRMD stock?
Wall Street analysts predict CRMD stock could reach $17.00 in the next 12 months. This represents a 45.4% increase from the current price of $11.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CorMedix Inc.'s business model?
CorMedix Inc. generates revenue by developing and commercializing therapeutic products, particularly focusing on its flagship product, Defencath, which aims to prevent catheter-related bloodstream infections. The company targets a significant medical need and seeks regulatory approvals and partnerships to enhance its market presence and product applications.
What is the highest forecasted price for CRMD CorMedix Inc.?
The highest price target for CRMD is $20.00 from at , which represents a 71.1% increase from the current price of $11.69.
What is the lowest forecasted price for CRMD CorMedix Inc.?
The lowest price target for CRMD is $13.00 from Brandon Folkes at Rodman & Renshaw, which represents a 11.2% increase from the current price of $11.69.
What is the overall CRMD consensus from analysts for CorMedix Inc.?
The overall analyst consensus for CRMD is bullish. Out of 12 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are CRMD stock price projections?
Stock price projections, including those for CorMedix Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 2:56 AM UTC